Poster Exhibition

Monday, 4 August 2008

Evaluation of ARV delivery outcome in resource constrained settings

Presentation type	Presentation day	Track	Poster Group	Text
All Oral abstracts Poster Discussions Poster Exhibition CD-ROM	All Sunday, 3 August 2008 Monday, 4 August 2008 Tuesday, 5 August 2008 Wednesday, 6 August 2008 Thursday, 7 August 2008 Friday, 8 August 2008	All A B C D E	All Access and availability of HIV/AIDS treatment and care, health services and mental health Access to therapy and strategies and models of delivery Acute early infection including infectivity Adherence Advocacy and lobbying by civil society, affected communities and PLWHAs Animal and cellular models of HIV pathogenesis Animal models for vaccine development Blood, organ and tissue safety Capacity building for HIV prevention research Capacity building for leadership and advocacy Clinical trials and antiretroviral therapy Community participation in research Compartmentalization Concepts of immune based therapy Cross-national comparisons Diagnosis, and disclosure of HIV disease Economic and human development dimensions of the epidemic Economic evaluation of prevention, care and mitigation programmes (including cost effectiveness) Economic strengthening initiatives (including micro-finance, health insurance, etc.) Efficiency and equity in access to treatment and prevention Epidemiology of HIV-1 and HIV-2 subtypes spreading Epidemiology of sexually transmitted infections (STI) and HIV Epidemiology of tuberculosis and HIV Epidemiology of viral hepatitis and HIV co-infection Epidemiology of vulnerabilities to HIV Ethical issues in prevention research Ethics (including research, clinical, public health and professional ethics) Ethnographic methods in HIV/AIDS research Evaluation of ARV delivery outcome in resource constrained settings Globalization and its effects, including structural adjustment and health sector reform HIV diversity and response to ARV HIV seroepidemiologic studies HIV/AIDS and the workplace, unemployment, return to work and rehabilitation HIV-specific cellular immunity HIV-specific humoral immunity Host genetic and HIV evolution Human resources and health systems Impact of donor agencies and policies on national responses Indigenous people and HIV Innate immunity Interventions to prevent mother-to-child transmission Intracellular restriction of HIV replication Male and female condoms and other physical barriers Male circumcision Maturation and assembly Mechanisms of immune dysfunction Media and cultural representations Methods for measuring vulnerability and social inequality Methods in social epidemiology Modeling Monitoring and evaluation of policies and their impact on PLWHA, affected communities and vulnerable populations Natural history, progression and survival Novel research designs in epidemiology Novel research designs in prevention research Pharmacology, pharmacokinetics, drug formulations Population-based surveys with HIV testing Provision of care, diagnosis and treatment for HIV exposed Risk behaviour, quality of life and access to care in harm reduction approaches Risk factors for acquisition of HIV Risk factors for infectivity, susceptibility, progression and transmission of HIV Roles and responsibilities of PLWHAs and vulnerable populations Roles and responsibilities of the state, civil society and private and business sectors Social and behavioural change theories, limits and possibilities Social class, poverty and socioeconomic stratification Socio-historical analyses of HIV/AIDS: the third decade Sustainability of ART programmes and adherence in developing countries Sustainability of financing Trade, patents and pharmaceutical production and availability Trends in morbidity and mortality Viral and host factors in long-term non progressors Viral dynamics and fitness Viral entry and tropism Viral regulatory genes Vulnerability reduction

MOPE0054 Abstract Two-year treatment outcomes of the first-line antiretroviral therapy programme in India B. Rewari1, D. Bachani1, R. Garg2, A. Despande3, S. Rajasekharan4, K.V. Emmanuel5, L. Hegg2, P. Chan6, S. Rao1 1National AIDS Control Organisation, Ministry of Health and Family Welfare, Government of India, New Delhi, India, 2World Health Organisation, Regional Office for South-east Asia, New Delhi, India, 3Sir J.J. Hospital, Department of Medicine, Mumbai, India, 4General Hospital for Thoracic Medicine (GHTM) Tambaram, Chennai, India, 5Osmania Medical College Hospital, Department of Medicine, Hyderabad, India, 6World Health Organisation, India Country Office, New Delhi, India MOPE0058 Abstract Feasibility and efficacy of HAART among hard-to-reach high-risk women in Burkina Faso C. Huet1, A. Ouedraogo1, I. Konaté1, J.-L. Ouedraogo1, I. Traoré1, F. Rouet1, A. Ouiminga1, A. Sanon1, R. Diallo1, P. Mayaud2, N. Nagot2, P. Van De Perre3, for the ANRS 1222 Yerelon Study Group 1Centre Muraz, Bobo-Dioulasso, Burkina Faso, 2London School of Hygiene & Tropical Medicine, London, United Kingdom, 3Université Montpellier 1, EA 4205 Transmission, Pathogenèse et Prévention de l’Infection par le VIH, Montpellier, France MOPE0052 Abstract Rate of mortality, loss to follow up, viral suppression and maintenance of initial HAART regimen at 2 years in 3321 Chilean patients C. Cortes, M. Wolff, C. Beltran, C. Chain, E. Daube, R. Northland Chilean AIDS Cohort, Santiago, Chile MOPE0048 Abstract Discordant responses to antiretroviral treatment: prevalence, risk factors and associated mortality in Rwanda J. van Griensven1, F. Rasschaert2, A. Asiimwe3, R. Zachariah2 1Medecins Sans Frontieres, Kigali, Rwanda, 2Medecins Sans Frontieres, Brussels, Belgium, 3TRAC, Kigali, Rwanda MOPE0074 Abstract Comparison of clinical and epidemiological characteristics and response to HAART IN HIV positive patients; Time period 2004/2005 vs 2006/2007 D. Iglesias1, L. Otero1, B. Magnifico1, L. Lynen2, J. Echevarría1, E. Gotuzzo1 1Instituto de Medicina Tropical 'Alexander von Humboldt', Lima, Peru, 2Instituut voor Tropische Geneeskunde, Clinical Sciences, Antwerp, Belgium MOPE0047 Abstract Effectiveness of antiretroviral treatment program in Georgia T. Tsertsvadze, L. Sharvadze, N. Chkhartishvili, N. Bolokadze, P. Gabunia, N. Dvali, M. Karchava, E. Dolmazashvili, O. Chokoshvili, A. Abutidze Infectious Diseases, AIDS & Clinical Immunology Research Center, Tbilisi, Georgia MOPE0045 Abstract A Simplified tool for measuring adherence to highly active antiretroviral therapy (HAART) in resource limited setting. The experience of Maragua District Hospital, Kenya G. Nzioka1, J. Makau1, Z. Ngari1, E. Kwena1, J. Kamau1, P. Nyagah1, E. Muketo2, V. Torres-Feced3, P. Mugo1, M. Kamande1, P. Mwangi1 1Ministry of Health, Maragua, Kenya, 2Family Health Options, Nairobi, Kenya, 3Vihda Association, Central Province, Kenya MOPE0056 Abstract Long-term outcomes for the first one thousand patients receiving ART in Haiti P.D. Leger1, M. Charles2, C. Guiteau3, P. Severe4, D. Fitzgerald5, J.W. Pape5, W. Johnson6 1GHESKIO Centers, ARV/Clinical Research, Port-au-Prince, Haiti, 2GHESKIO Centers/ Cornell University, ARV/Research/Biology, Port-au-Prince, Haiti, 3GHESKIO Centers, ARV, Port-au-Prince, Haiti, 4GHESKIO Centers, ARV/Research, Port-au-Prince, Haiti, 5GHESKIO Centers, Port-au-Prince, Haiti, 6Cornell University, International Medicine, New York, United States MOPE0073 Abstract Low adherence rate with antiretroviral treatment regimens in HIV positive persons living in the Dominican Republic E. Perez-Then1, R. Sanchez2, J. Ruiz3, A. Diaz1, T. Brewer4, G. Shor-Posner4 1Centro Nacional de Investigaciones en Salud Materno Infantil (CENISMI), Santo Domingo, Dominican Republic, 2Direccion General para el Control de las Enfermedades de Transmision Sexual y SIDA (DIGECITSS), Santo Domingo, Dominican Republic, 3Consejo Presidencial del SIDA (COPRESIDA), Santo Domingo, Dominican Republic, 4Fogarty International Research and Training Program, Miami, United States MOPE0051 Abstract Changes in plasma (PVL) and genital tract (GTVL) HIV-1 viral loads in Cambodian women initiating generic antiretroviral therapy K. Lim1, J. Harwell2, P. Srey1, S. Thay1, L. Tharpe3, J. Ingersoll4, A. Caliendo4, S. Cu-Uvin2 1Sihanouk Hospital Center of HOPE, Phnom Penh, Cambodia, 2Brown University, Providence, United States, 3Vanderbilt University, Nashville, United States, 4Emory University, Atlanta, United States MOPE0072 Abstract Associated factors to CD4 cell count recovery in adult naïve patients receiving HAART in Peru P. Caballero1, J. Peinado2 1National Institute of Health, National Center for Public Health, Lima, Peru, 2Asociación Impacta, Lima, Peru MOPE0040 Abstract Viral loads and HIV drug resistance (HIVDR) patterns in ART patients with clinical or immunological failures at outpatient clinics in Ho Chi Minh City, Vietnam K. Nguyen van1, H. Le Thi1, N. Do Thi1, T. Lai Vinh2, T. Huynh Thu2 1Ministry of Health, Vietnam Administration for HIV/AIDS control, Hanoi, Viet Nam, 2Provincial AIDS Committee, Ho Chi Minh City, Viet Nam MOPE0063 Abstract Retrospective analysis of patients who died after starting anti retroviral treatment in a resource limited setting in South India R.P. Shivaswamy1, B. Mysore Anantharamiah2, S. Seetharam3, C. Thangsing4, N. Mohanty4, H. Chang5 1Swami Vivekananda Youth Movement, Internal Medicine, Mysore, India, 2Swami Vivekananda Youth Movement, Mysore, India, 3Swami Vivekananda Youth Movement, Pathology, Mysore, India, 4AIDS Healthcare Foundation, New Delhi, India, 5AIDS Healthcare Foundation, Amsterdam, Netherlands MOPE0068 Abstract Antiretroviral drugs management system in Senegal A. Diouf1, T.M. Diouf2, C. Bayer3, K. Diop4 1Centre Régional de Recherche et de Formation sur la Prise en Charge Clinique du VIH/sida et Maladies Associées (CRCFP), Infectious Diseases, Dakar, Senegal, 2Japanese International Cooperation Agency (JICA), Dakar, Senegal, 3West African Health Organization (WAHO), Tulane University, Bobo Dioulasso, Burkina Faso, 4Division de Lutte contre le Sida et les IST (DLSI), Dakar, Senegal MOPE0053 Abstract Baseline correlates of pre-antiretrovial therapy nutritional status among HIV-infected adults in diverse regions of the world A. Andrade1, L. Smeaton2, T. Campbell3, R. Bollinger1, R. Mitsuyasu4, J. Lama5, K. Klingman6, J. Hakim7, N. Kumarasamy8, V. De Gruttola2, E. Swann9, T. Flanigan10, C. Kanyama11, S. Godbole12, A. Gupta1 1Johns Hopkins University, Medicine, Baltimore, United States, 2Harvard School of Public Health, Statistical & Data Analysis Center, Boston, United States, 3University of Colorado Health, Medicine, Denver, United States, 4UCLA CARE Center, Medicine, Los Angeles, United States, 5Asociación Civil Impacta Salud y Educación, Medicine, Lima, Peru, 6TRP, DAIDS, NIAID, NIH, AIDS Research Branch, Bethesda, United States, 7University of Zimbabwe, Medicine, Harare, Zimbabwe, 8Centre for AIDS Research &, Medicine, Tharamani, India, 9VRP/DAIDS/NIAID/NIH/DHHS, Vaccine Clinical Research Branch, Bethesda, United States, 10The Miriam Hospital, Medicine, Providence, United States, 11University of North Carolina Project, Lilongwe, Malawi, 12National AIDS Research Institute Clinic at NIV, Pune, India MOPE0065 Abstract Mortality and morbidity among HIV-infected patients during the first five years of a multi-country HIV workplace programme in Africa S. Van der Borght1, P. Clevenbergh2, H. Rijckborst1, P. Nsalou3, J. Lange2, T. Rinke de Wit2, M. Schim van der Loeff4 1Heineken International, Health Affairs, Amsterdam, Netherlands, 2PharmAccess Foundation, Amsterdam, Netherlands, 3Brasseries du Congo, Service Medical, Pointe Noire, Congo, 4Academic Medical Center, University of Amsterdam, Centre for Poverty-related Communicable Diseases, Amsterdam, Netherlands MOPE0064 Abstract Five-year HAART outcomes among HIV-1C infected adults in Botswana´s National ARV Treatment program H. Bussmann1, N. Grundmann1, C.W. Wester1, V. DeGruttola2, T. Gaolathe3, N. Ndwapi4, M. Mine3, C. Snyman3, J. Puvimanasinghe4, J. Makhema1, K. Seipone5, L. Mazhani5, M. Essex6, R. Marlink6 1Botswana-Harvard Partnership, Gaborone, Botswana, 2Harvard School of Public Health, Biostatistics, Boston, United States, 3Botswana-Harvard Partnership-PEPFAR, Gaborone, Botswana, 4Botswana Ministry of Health; Botswana-Harvard Partnership, Gaborone, Botswana, 5Botswana Ministry of Health, Gaborone, Botswana, 6Harvard School of Public Health, Immunology and Infectious Diseases, Boston, United States MOPE0046 Abstract 24 and 36 month outcomes among HIV-infected individuals starting antiretroviral therapy in a workplace program in South Africa C. Innes1, S. Charalambous1, M. Maraisane1, S. Senoge1, P. Seatlanyane1, K. Fielding2, A. Grant2, G. Churchyard1 1Aurum Institute for Health Research, HIV Care & Treatment, Johannesburg, South Africa, 2London School of Hygiene & Tropical Medicine, London, United Kingdom MOPE0050 Abstract Long term durability of ART: 36 month on treatment analysis of 338 patients in Sub-Saharan Africa K. Stafford1, M. Ivy2, S. Medina-Moreno1, S. Were2, A. Amoroso1 1University of Maryland School of Medicine, Institute of Human Virology, Baltimore, United States, 2University of Maryland School of Medicine, Institute of Human Virology, Nairobi, Kenya MOPE0041 Abstract Survival and weight gain in a community-based pediatric ART program in rural Rwanda S. Stulac1, J. Lewey2, B. Bucyibaruta1, G. Iyamungu1, J.B. Kanyamuhanda1, A. Manzi1, A. Kayirangwa1, M. Rich3, J. Mukherjee4, P. Farmer2 1Partners in Health, Pediatrics, Rwinkwavu, Rwanda, 2Harvard Medical School, Boston, United States, 3Partners in Health, Rwinkwavu, Rwanda, 4Brigham and Women's Hospital, Boston, United States MOPE0057 Abstract Failure of highly active antiretroviral therapy (HAART) in Jamaican children: issues for the WHO approach in developing countries R.B. Pierre1, I. Singh-Minott2, J. Moore2, D. Carrington3, K. Harvey3, M. Smikle2, J.P. Figueroa3, C.D.C. Christie2, Kingston Pediatric & Perinatal HIV/AIDS Program (KPAIDS) Research Group 1University of the West Indies, Obstetrics, Gynaecology & Child Health, Kingston, Jamaica, 2University of the West Indies, Kingston, Jamaica, 3Ministry of Health, Kingston, Jamaica MOPE0066 Abstract Improving survival of children with AIDS: continuing improvement in Brazil L.H. Matida1, A.N. Ramos Jr2, H.H.S. Marques3, M. Della Negra4, R.C.M. Succi5, N. Hearst6, National Group of Survival Study in Children with HIV/AIDS 1Program of STD/AIDS, Sao Paulo, Brasil, Sao Paulo, Brazil, 2Universidade Federal do Ceara, Fortaleza, Brazil, 3Universidade Sao Paulo, Sao Paulo, Brazil, 4Instituto de Infectologia Emilio Ribas, Sao Paulo, Brazil, 5Universidade Federal Sao Paulo, Sao Paulo, Brazil, 6University California San Francisco, San Francisco, United States MOPE0055 Abstract Efficacy of treatment-mediated viral suppression on CD4+ T cell recovery and T cell activation in HIV-infected Ugandans P. Hunt1, H. Cao2, D. Bangsberg1, I. Andia3, L. Pepper3, B. Bwana3, N. Emenyonu1, T. Neilands4, S. Deeks1, J. Martin4 1University of California San Francisco, Internal Medicine, San Francisco, United States, 2California Department of Health Services, Richmond, United States, 3Mbarara University, Internal Medicine, Mbarara, Uganda, 4University of California San Francisco, Epidemiology and Biostatistics, San Francisco, United States MOPE0070 Abstract Antiretroviral therapy in adults and adolescents with AIDS in Haiti from 2003-2007: a cohort analysis G. Rebick1, M. Charles1, P. Leger1, C. Guiteau1, P. Severe1, D.W. Fitzgerald2, J.W. Pape2, W.D. Johnson2, P.F. Wright3 1GHESKIO (Groupe Haïtien d'Etude du Sarcome de Kaposi et des Infections Opportunistes), Port-au-Prince, Haiti, 2Cornell Weill Medical College, Division of International Medicine and Infectious Diseases, New York, United States, 3Vanderbilt University, Division of Pediatric Infectious Diseases, Nashville, United States MOPE0039 Abstract Quality-of-care indicators for international HIV/AIDS care: scaling up beyond the numbers D. Olson, B. Lokuge, G. Elder Doctors Without Borders/Medecins Sans Frontieres (MSF), New York, United States MOPE0067 Abstract HIVQUAL-Uganda: improving peadiatric HIV quality of care in post-conflict regions of Northern Uganda G. Kayita Lumbuye1, J. Ssendiwala2, R. Oketch3, R. Loreka4, M. Palumbo5, B. Agins5, E. Madraa2, R. Gass6, J. Kayita7 1Ministry of Health, Clinical Services, STD/AIDS Control Program, Kampala, Uganda, 2Ministry of Health, Clinical Services, Kampala, Uganda, 3UNICEF Country Office, HIV/AIDS, Kampala, Uganda, 4MoH/CDC, HIV/AIDS, Bangkok, Thailand, 5NYSDOH, AIDS Institute, HIVQUAL-I, New York, United States, 6UNICEF Headquarters, HIV/AIDS Care and Support, New York, United States, 7UNICEF Eastern & Southern Africa Regional Office, Pediatrics HIV/AIDS, Nairobi, Kenya MOPE0060 Abstract Reasons for change of first potent antiretroviral therapy in HIV-1-infected patients in 5 sites throughout the Caribbean and Latin America C. Cesar1, B. Shepherd2, M. Schechter3, M. Wolff4, J. Pape5, E. Gotuzzo6, M. Bacon7, C. McGowan8, D. Masys9, P. Cahn1, IeDEA Region 2: Caribbean, Central and South America 1Fundacion Huesped, Investigaciones Clinicas, Buenos Aires, Argentina, 2University of Vanderbilt, Biostatistics, Nashville, United States, 3Universidade Federal do Rio de Janeiro, Projeto Praça Onze, Rio de Janeiro, Brazil, 4University of Chile School of Medicine, Medicine, Santiago, Chile, 5GHESKIO/Weill Medical College of Cornell University, Port-au-Prince, Haiti, 6Instituto de Medicina Tropical Alexander von Humboldt, Lima, Peru, 7HJF-NIAID/DAIDS, Epidemiology, Bethesda, United States, 8University of Vanderbilt, Infectious Diseases, Nashville, United States, 9University of Vanderbilt, Biomedical Informatics, Nashville, United States MOPE0061 Abstract Treatment failure to first-line regimens in adults attending South African public sector antiretroviral services A. Suleman, A. Ramkissoon Reproductive Health and HIV Research Unit, durban, South Africa MOPE0044 Abstract Antiretroviral regimen substitutions and switches due to drug toxicity and treatment failure: a national survey three years after the start of antiretroviral therapy roll-out in Malawi A. Jahn1, S. Makombe2, J. Mwafilaso3, C. Gondwe3, E. Schouten2, K. Kamoto2, A.D. Harries2 1The Lighthouse Trust, I-TECH Malawi, Monitoring and Evaluation, Lilongwe, Malawi, 2Ministry of Health, HIV Unit, Lilongwe, Malawi, 3The Lighthouse Trust, Monitoring and Evaluation, Lilongwe, Malawi MOPE0042 Abstract Retention of HIV-infected patients on antiretroviral therapy in 11 clinical centres within the International epidemiologic databases to evaluate AIDS West Africa collaboration M.D. Zannou1, D.K. Ekouevi2, F.O. Ba-Gomis3, M. Maiga4, A. Minga5, H. Traoré6, K. Peterson7, C. Kanga-Koffi8, C. Amani-Bosse9, J.F. Etard10, E. Balestre11, P.S. Sow12, E. Messou13, F. Dabis11, S. Eholie14, E. Bissagnene14, IeDEA West Africa Study Group 1Centre de Prise en Charge des Personnes vivant avec le VIH, CNHU Hubert Maga, Cotonou, Benin, 2Programme PAC-CI, CHU de Treichville, Abidjan, Cote D'Ivoire, 3Centre Intégré de Recherche Bioclinique d’Abidjan (CIRBA), Abidjan, Cote D'Ivoire, 4Service d’Hépato-Gastro-Entérologie, Hôpital Gabriel Touré, Bamako, Mali, 5Centre Médical de Suivi de Donneurs de Sang/CNTS/PRIMO-CI, Abidjan, Cote D'Ivoire, 6Centre de Prise en Charge des Personnes vivant avec le VIH, Hôpital du point G, Bamako, Mali, 7Fajara Cohort, Banjul, Gambia, 8Unité de Soins Ambulatoires et de Conseil (USAC), Abidjan, Cote D'Ivoire, 9ACONDA-MTCT+ Adultes, Abidjan, Cote D'Ivoire, 10ANRS 1215 Cohort, Dakar, Senegal, 11Institut de Santé Publique d'Epidémiologie et de Developpement, Université Victor Segalen, Bordeaux, France, 12Service des Maladies Infectieuses, CHU de FANN/ ISAARV, Dakar, Senegal, 13ACONDA-CePReF, Adultes, Abidjan, Cote D'Ivoire, 14Service de Maladies infectieuses et Tropicales (SMIT), CHU de Treichville, Abidjan, Cote D'Ivoire MOPE0071 Abstract Quality of life of people living with AIDS receiving antiretroviral therapy in Cuba C. Aragones Lopez1, A. Castro2, J.R. Campos Diaz1, Y. Khawja2, J. Perez Avila3 1Tropical Medicine Institute, Biostatistics and Informatics, Havana, Cuba, 2Harvard Medical School, Boston, United States, 3Tropical Medicine Institute, Hospital, Havana, Cuba MOPE0062 Abstract Effect of highly active antiretroviral therapy on mortality in HIV-infected former plasma donors in China F. Zhang1, Z. Dou1, L. Yu1, J. Xu2, J.H. Jiao2, N. Wang1, Y. Ma1, Y. Zhao1, H. Zhao3, R.Y. Chen4 1National Center for AIDS/STD Control and Prevention, China CDC, Beijing, China, 2Westat, Inc., Rockville, United States, 3Ditan Hospital, Beijing, China, 4National Institute of Allergy and Infectious Diseases, National Institutes of Health, Beijing, China MOPE0059 Abstract HIV/AIDS survival in adults and children under HAART in rural Malawi P. Nkhoma1, M. McGuire1, L. Ahoua2, S. Goossens1, A. Kabwinja1, M. Le Paih1, A. Munger1, J. Mpunga3, A. Jeannin4, E. Szumilin4, K. Kamoto5, A.D. Harries5 1Médecins Sans Frontières, Chiradzulu, Malawi, 2Epicentre, Paris, France, 3Ministry of Health, Chiradzulu, Malawi, 4Médecins Sans Frontières, Paris, France, 5Ministry of Health, HIV Unit, Lilongwe, Malawi MOPE0049 Abstract Increased baseline body weight is a risk factor associated with virological failure while on antiretroviral treatment J. van Griensven1, F. Rasschaert2, E.F. Atté1, R. Zachariah2 1Medecins Sans Frontieres, Kigali, Rwanda, 2Medecins Sans Frontieres, Brussels, Belgium MOPE0043 Abstract Immuno-virological and toxicity outcomes of HIV-infected patients after 48 months of ART in Phnom Penh, Cambodia B. Schramm1, S. Balkan2, L. Som3, E. Nerreniet4, C.C. Nget5, S. Moeung5, P. Narom5, L. Pinoges1, L. Ferradini3, M. Pujades-Rodríguez1 1Epicentre, Paris, France, 2Médecins Sans Frontières, Paris, France, 3Médecins Sans Frontières, Phnom Penh, Cambodia, 4Pasteur Institute, HIV/Hepatitis laboratory, Phnom Penh, Cambodia, 5Khmer-Soviet Friendship Hospital, Phnom Penh, Cambodia MOPE0069 Abstract Treatment outcomes comparison of AIDSRelief supported sites initiated in the first and second years of PEPFAR A. Amoroso1, I. Mwangi2, S. Medina-Moreno1, S. Were2, K. Stafford1 1University of Maryland School of Medicine, Institute of Human Virology, Baltimore, United States, 2University of Maryland School of Medicine, Institute of Human Virology, Nairobi, Kenya